Literature DB >> 77715

Antenatal prophylaxis of Rh isoimmunization: 28-weeks'-gestation service program.

J M Bowman, J M Pollock.   

Abstract

Two (0.18%) of 1086 Rh-negative primigravidas or multigravidas treated similarly in all previous pregnancies, who were given a single injection of Rh immune globulin (300 mug) at 28 weeks' gestation and subsequently were delivered of Rh-positive babies, had demonstrable Rh isoimmunization at the time of that injection and must be considered "logistic" failures of antenatal prophylaxis. The remaining 1084 (who were treated again after delivery) had no evidence of Rh isoimmunization at delivery and none of the 512 screened at 6 months after delivery appeared to be immunized. If the 28th-week injection had not been protective, one would have expected 14 of the 1084 to have been demonstrably Rh isoimmunized and evidence of Rh isoimmunization to have persisted in 6 of the 512 observed 6 months after delivery.Six of 719 Rh-negative multigravidas who had not received Rh immune globulin after previous pregnancies or had been treated only after delivery showed evidence of Rh isoimmunization despite a single injection of Rh immune globulin at 28 weeks in a subsequent pregnancy. In three of the six the cause was most likely "sensibilization" due to previous exposure to Rh-positive blood or an untreated Rh-positive pregnancy. in 3 of the remaining 716 (0.42%) there may have been true failure of antenatal Rh prophylaxis administered at the 28th week. One would have expected this figure to be 12 of 716 if antenatal Rh prophylaxis at 28 weeks' gestation were totally unsuccessful.It is concluded that a single intramuscular injection of Rh immune globulin, 300 mug, is 88% effective in preventing Rh isoimmunization during pregnancy in Rh-negative primigravidas and in multigravidas treated antenatally in all previous pregnancies, and is 75% effective in preventing Rh isoimmunization in Rh-negative multigravidas untreated during previous pregnancies. The majority of failures are due to Rh isoimmunization during pregnancy prior to antenatal prophylaxis at 28 weeks.

Mesh:

Substances:

Year:  1978        PMID: 77715      PMCID: PMC1818036     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  10 in total

Review 1.  The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation.

Authors:  Giancarlo Maria Liumbruno; Angelo D'Alessandro; Federica Rea; Vanessa Piccinini; Liviana Catalano; Gabriele Calizzani; Simonetta Pupella; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2010-01       Impact factor: 3.443

Review 2.  Anti-D prophylaxis in 1997: the Edinburgh Consensus Statement.

Authors:  D James
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-05       Impact factor: 5.747

3.  Pump up the volume? The routine early use of colloid in very preterm infants.

Authors:  P Hope
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-05       Impact factor: 5.747

4.  Turnover rate of anti-D IgG injected during pregnancy.

Authors:  J Eklund; M Hermann; H Kjellman; P Pohja
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-20

Review 5.  Approach to red blood cell antibody testing during pregnancy: Answers to commonly asked questions.

Authors:  Leigh Minuk; Gwen Clarke; Lani Lieberman
Journal:  Can Fam Physician       Date:  2020-07       Impact factor: 3.275

6.  Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: meta-analyses adjusted for differences in study design and quality.

Authors:  Rebecca M Turner; Myfanwy Lloyd-Jones; Dilly O C Anumba; Gordon C S Smith; David J Spiegelhalter; Hazel Squires; John W Stevens; Michael J Sweeting; Stanislaw J Urbaniak; Robert Webster; Simon G Thompson
Journal:  PLoS One       Date:  2012-02-03       Impact factor: 3.240

7.  Non-invasive prenatal rhesus D genotyping using cell-free foetal DNA.

Authors:  Riyaz Ahmad Rather; Veena Dhawan; Subhas Chandra Saha
Journal:  Indian J Med Res       Date:  2019-07       Impact factor: 2.375

8.  Clinical value of different anti-D immunoglobulin strategies for preventing Rh hemolytic disease of the fetus and newborn: A network meta-analysis.

Authors:  Xiaohui Xie; Qiurong Fu; Ziwei Bao; Yi Zhang; Dan Zhou
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

9.  Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis.

Authors:  J M Koelewijn; M de Haas; T G M Vrijkotte; C E van der Schoot; G J Bonsel
Journal:  BJOG       Date:  2009-06-17       Impact factor: 6.531

10.  Bias modelling in evidence synthesis.

Authors:  Rebecca M Turner; David J Spiegelhalter; Gordon C S Smith; Simon G Thompson
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2009-01       Impact factor: 2.483

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.